Drug intelligence / Profile preview

18F-BMS-986327

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-BMS-986327 is a **radiolabeled positron emission tomography (PET) ligand** designed for non-invasive imaging and quantification of **lysophosphatidic acid receptor 1 (LPA1)** in vivo, especially in the context of pulmonary fibrosis and related clinical research. It allows visualization of LPA1 receptor distribution and occupancy and is primarily utilized in diagnostic research settings, not as a therapeutic agent. Developed for use in PET imaging studies, its mechanism of action involves acting as a PET imaging enhancer and radionuclide imaging agent targeting LPA1 for diagnostic purposes[2][4][5].

Brand names: 18F-BMS-986327
Other names: 18F BMS 986327

Targets

LPAR1 (Lysophosphatidic acid receptor 1)

Beyond the preview

Go deeper on 18F-BMS-986327.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-BMS-986327.

Explore the full profile